Department of Medicine, Capital Health Regional Medical Center-FULD, 750 Brunswick Avenue, Trenton, NJ 08638, USA.
J Cardiovasc Transl Res. 2013 Aug;6(4):471-84. doi: 10.1007/s12265-013-9465-0. Epub 2013 Apr 20.
Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality research indicating its diagnostic and prognostic capabilities, biomarkers are excellent adjuncts to manage patients with HF. Their superiority lies mainly in their reflection of ongoing pathophysiological events at a cellular level. Monitoring biomarker levels has been shown to provide incremental information on the progression of disease, thus allowing to better tailor treatment and management. Several biomarkers have gained attention in the past decade and continuing research demonstrates the specificity of each biomarker to be used on its own or in combination to improve diagnostic accuracy. This review will provide an insight into the role of such biomarkers, which are widely studied in the setting of HF so as to delineate their role in diagnosing, prognosticating, and titrating HF therapy.
生物标志物检测在心力衰竭（HF）患者中迅速发展。高质量的研究表明其具有诊断和预后能力，生物标志物是管理 HF 患者的极好辅助手段。它们的优势主要在于它们反映了细胞水平上持续的病理生理事件。监测生物标志物水平已被证明可以提供疾病进展的增量信息，从而能够更好地调整治疗和管理。在过去十年中，有几种生物标志物引起了人们的关注，持续的研究表明，每种生物标志物都具有特异性，可以单独使用或组合使用，以提高诊断准确性。这篇综述将深入探讨这些生物标志物的作用，这些标志物在 HF 环境中得到了广泛研究，以阐明它们在诊断、预后和调整 HF 治疗中的作用。
